IronBridge Private Wealth’s Emergent Biosolutions EBS Stock Holding History

IronBridge Private Wealth’s Portfolio EBS Stock Details EBS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-103	Closed	-$5K	–	298
2021 Q3	$5K	Hold	103	–	–	﹤0.01%	209
2021 Q2	$6K	Hold	103	–	–	﹤0.01%	195
2021 Q1	$10K	Hold	103	–	–	0.01%	154
2020 Q4	$9K	Buy	+103	New	+$9.45K	0.01%	150

Other funds holding EBS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

IronBridge Private Wealth's EBS Position: Q4 2021 in Review

IronBridge Private Wealth sold out of Emergent Biosolutions (EBS) in Q4 2021, closing a stake of 103 shares — an estimated $5K sold.

IronBridge Private Wealth first reported a position in EBS in Q4 2020 and held it in 4 quarters. The position peaked at $10K in Q1 2021. 254 funds tracked by Wall St. Rank hold EBS as of Q4 2021.

IronBridge Private Wealth reported no remaining Emergent Biosolutions position as of Q4 2021 after selling out during the quarter.
IronBridge Private Wealth sold 103 Emergent Biosolutions shares in Q4 2021, an estimated $5K.
IronBridge Private Wealth first reported a position in Emergent Biosolutions in Q4 2020 and held it in 4 quarters.
IronBridge Private Wealth's Emergent Biosolutions position peaked at $10K in Q1 2021.
254 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q4 2021.

Based on IronBridge Private Wealth's 13F filing for Q4 2021, filed 17 Feb 2022.